Clinical Trial Update: An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pomalidomide and low-dose dexamethasone with or without elotuzumab in relapsed/refractory multiple myeloma completed in 2019 with poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elotuzumab (elotuzumab)
• Pomalidomide (Pomalidomide)
• low-dose dexamethasone (dexamethasone)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2019-06-03